GRACE :: Lung Cancer

Search cancerGRACE.org

Greg Riely

GRACE Video

Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West

Share

AR_2015_QA_West_Riely_Sequencing_Older_Newer_EGFR_Agents

 

Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE Video

Emerging Options for T790M-Positive Acquired Resistance

Share

AR_2015_Riely_T790M_Positive_Acquired_Resistance_Options

 

Acquired resistance in EGFR patients is often driven by the T790M mutation. T790M-positive tumors respond differently to treatments than T790M-negative tumors. Dr. Greg Riely details how each status can predict patients’ responses to current treatments.

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE Video

Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn

Share

AR_2015_QA_Riely_Horn_Acquired_Resistance

 

Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE Video

What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?

Share

AR_2015_Riely_Immunotherapy_Driver_Mutation_Advanced_NSCLC

 

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE Video

First Line Treatment of EGFR Mutation-Positive NSCLC

Share
GRACE Cancer Video Library - Lung

GCVL_LU_First_Line_Treatment_EGFR_Mutation-Positive_NSCLC

 

MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

When we identify a patient with an EGFR mutant form of lung cancer, we know that there’s a mutation in their tumor. That helps us figure out the first line of treatment — the initial therapy for patients. Now, some of the initial work identifying drugs for patients with EGFR mutant lung cancer focused on patients who had had multiple prior therapies, but over the last five years we’ve had a luxury of big, randomized clinical trials where we take hundreds of patients and randomize half of them to treatment with chemotherapy, and half of them to treatment with EGFR tyrosine-kinase inhibitors — drugs like erlotinib, gefitinib and afatinib.

When we look at those trial results, we see really remarkable improvements in the chance of the tumor shrinking, so that it’s much more likely that with these oral treatments for lung cancer, like erlotinib, gefitinib, or afatinib, that the tumors will shrink — much more likely than with chemotherapy. Importantly, it’s also shown that, from these trials, that we see much longer time until the cancer grows. So, taking a pill leads to longer disease control than we see with IV chemotherapies.


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243